Altogen Labs, a GLP-compliant research laboratory, offers over 100 internally validated xenograft models, including cell line-derived xenografts (CDX) and patient-derived xenografts (PDX), as well as syngeneic xenograft models, which are vital for cancer research and IND. These xenograft IND testing services are conducted to gauge the potency and effectiveness of emerging anti-cancer compounds, largely based on the rate of tumor growth after engraftment. The most recent additions to the collection of xenograft models include T47D (a breast cancer model), SKNAS (a neuroblastoma xenograft), HL60 (a leukemia model), and H460 (a lung cancer xenograft model).
Xenografting, the process of transplanting cells from one species (usually human tumor cells) into another (typically immunodeficient laboratory mice), is a critical technique in preclinical studies, aiding the exploration of new cancer treatments in terms of both efficacy and safety. Xenotransplantation presents more accuracy and precision in representing tumors and evaluating anti-cancer drug effectiveness compared to in vitro studies. With vast experience in developing human tumor xenografts, Altogen Labs also offers preclinical safety and efficacy xenograft studies to global biopharma industries and cancer research centers.
Since its inception in 2009, Altogen Labs has been providing a myriad of in vitro and in vivo studies for preclinical cancer research. Their services include over 100 internally validated xenograft models, development of stable cell lines within 28 days, in vivo RNAi and tissue-targeted delivery technology development services, biomolecule encapsulation, IC-50 assays, among other biology CRO laboratory studies. The broad range of preclinical services offered by Altogen Labs caters to their clients' specific requirements, extending from the initial study design phase to patent or regulatory submissions.
Preclinical CRO services include the development of stable cell lines within 28 days, gene expression and gene silencing (RNAi) studies, cell banking and cryopreservation services, toxicology, PK/PD, and more. Altogen Labs excels at generating stable cell lines within 28 days, a service highly sought after in research involving gene function, drug screening, and other areas, as the process is typically time-consuming and labor-intensive.
Our lab boasts over 100 in-house validated xenograft models designed to expedite the creation of innovative anti-cancer drugs and treatments for inflammation, infectious diseases, immunology, and obesity. Our team of scientists conduct an array of toxicity tests - acute, sub-chronic, and chronic - to gauge drug toxicity, offering thorough statistical and quantitative analysis to investigate toxic effects of potential drug candidates. Acute toxicology studies focus on assessing short-term toxicological impacts after a single substantial dose of a test compound. Meanwhile, sub-chronic toxicology studies involve Altogen Labs' scientists assessing the toxicity of chemicals after multiple small doses over a three-month period. Chronic toxicity tests delve into the potential harmful effects following repeated and extended exposure over several months to a year or more.
Understanding potential adverse impacts is crucial to achieving clinical effectiveness and safety for human use. In vivo efficacy and safety studies, using our wide range of xenograft models, analyze different dosage levels and drug administration routes to optimize the delivery and biodistribution of an investigational new drug (IND). Altogen Labs provides a diverse array of in vivo services for efficacy studies in the early stages of drug discovery and development of novel trerapies. Efficacy studies rely on validated xenograft (see list). Preclinical toxicology studies are carried out to determine the toxicity of a test compound and evaluate the therapeutic potential of a drug candidate prior to launching clinical trials (pharm/tox assays and in vivo toxicology studies).
About Altogen Labs
Austin-based, Altogen Labs (altogenlabs.com) is a contract research organization (CRO) that adheres to GLP standards. They offer a comprehensive range of services in biotechnology and preclinical pharmacology. The primary areas of focus for Altogen Labs are cancer research, drug development, and corresponding oncology CRO research services. Their offerings include, but are not limited to, biodistribution research studies, toxicology IND studies, analysis of gene function and gene expression, in vivo RNAi and tissue-targeted siRNA delivery services, along with the establishment of stable cell lines.
Contacts
Altogen Labs
Alex Fanelli, PhD
11200 Manchaca Rd, Suite 203
Austin TX 78748
Web: altogenlabs.com
